This preprint is under consideration at Infectious Agents and Cancer. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
ying xiang
Chongqing University Cancer Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-3500-6539
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Diffuse large B-cell lymphoma (DLBCL) represents a clinically heterogeneous disease. Models based on immunohistochemistry predict clinical outcomes. However, whether these immunophenotypes could be applied as a predictive indicator in AIDS-Related DLBCL remains unclear. To explore predictive immunophenotypes and their clinical implications in AIDS-related DLBCL, we analyzed patient samples treated 2008–2019 with R-CHOP/CHOP-like and central nervous system (CNS) prevention treatment for DLBCL with HIV infection in Chongqing cancer hospital. c-MYC, CD4 count, and co-expression of BCL-2 and c-MYC presented the potential of being predictive markers in the prognosis of AIDS-related DLBCL, while absolute lymphocyte count did not show any effects in clinical outcomes. Surprisingly, we found that BCL-2 and the germinal center b-cell (GCB) subtype also could predict the prognosis of AIDS-related DLBCL, which against previous studies. Thus, the specific mechanism of BCL-2 and GCB subtype in AIDS-related DLBCL still requires to be explored.
Keywords
DLBCL, AIDS, BCL-2
Figure 1
Figure 2
Figure 3
Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 22 Mar, 2021
No community comments so far
Review #1 received
Received 05 Apr, 2021
Reviewers invited
Invitations sent on 18 Mar, 2021
Reviewer #1 agreed
On 18 Mar, 2021
Editor assigned
On 09 Mar, 2021
Submission checks complete
On 09 Mar, 2021
Editor invited
On 09 Mar, 2021
First submitted
On 09 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
Learn more about our company.
This preprint is under consideration at Infectious Agents and Cancer. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
ying xiang
Chongqing University Cancer Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-3500-6539
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 22 Mar, 2021
No community comments so far
Review #1 received
Received 05 Apr, 2021
Reviewers invited
Invitations sent on 18 Mar, 2021
Reviewer #1 agreed
On 18 Mar, 2021
Editor assigned
On 09 Mar, 2021
Submission checks complete
On 09 Mar, 2021
Editor invited
On 09 Mar, 2021
First submitted
On 09 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Diffuse large B-cell lymphoma (DLBCL) represents a clinically heterogeneous disease. Models based on immunohistochemistry predict clinical outcomes. However, whether these immunophenotypes could be applied as a predictive indicator in AIDS-Related DLBCL remains unclear. To explore predictive immunophenotypes and their clinical implications in AIDS-related DLBCL, we analyzed patient samples treated 2008–2019 with R-CHOP/CHOP-like and central nervous system (CNS) prevention treatment for DLBCL with HIV infection in Chongqing cancer hospital. c-MYC, CD4 count, and co-expression of BCL-2 and c-MYC presented the potential of being predictive markers in the prognosis of AIDS-related DLBCL, while absolute lymphocyte count did not show any effects in clinical outcomes. Surprisingly, we found that BCL-2 and the germinal center b-cell (GCB) subtype also could predict the prognosis of AIDS-related DLBCL, which against previous studies. Thus, the specific mechanism of BCL-2 and GCB subtype in AIDS-related DLBCL still requires to be explored.
Figure 1
Figure 2
Figure 3
Figure 4
Loading...